EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSJJAG00000012190
Gene Symbol: ATP1A3
3 Cross references
134 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSJJAG00000017903
Gene Symbol: ATP1B1
3 Cross references
294 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSJJAG00000013283
Gene Symbol: ATP1B2
3 Cross references
274 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSJJAG00000015162
Gene Symbol: ATR
3 Cross references
206 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSJJAG00000010305
Gene Symbol: AXL
3 Cross references
197 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSJJAG00000020559
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSJJAG00000003950
Gene Symbol: BCL2
3 Cross references
227 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSJJAG00000015080
Gene Symbol: BCL2L1
2 Cross references
286 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSJJAG00000011614
Gene Symbol: BCR
3 Cross references
274 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSJJAG00000020585
Gene Symbol: BTK
3 Cross references
206 Possible Orthologues:

C-C Motif Chemokine Receptor 1

Ensembl ID : ENSJJAG00000001737
Gene Symbol: CCR1
2 Cross references
299 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSJJAG00000005584
Gene Symbol: CCR2
3 Cross references
286 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).